ESR1 and breast cancer: For instance, pembrolizumab administration followed by hypofractionated radiotherapy in patients with heavily pretreated metastatic TNBC reached the ORR of 17.6% (3 out of 17 patients) in the phase II trial [106], however, such treatment combination in ER+ BC patients showed no objective response [107].